ArticleBrain, behavior, and immunity2022
Exaggerated amygdala response to threat and association with immune hyperactivity in depression.
Article in Brain, behavior, and immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Effects of Dopaminergic Therapy with Levodopa (L-DOPA) on Fear and Anxiety-Related Circuits and Symptoms in Patients with Depression and Higher Inflammation.Brain, behavior, and immunity · 2026Trial
- Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial.Nature medicine · 2026Trial
- Neurofeedback for functional neurological disorders: future directions for research and clinical practice.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Protocol for a randomized, controlled trial of a bioactive dietary polyphenol preparation to promote resilience in healthy individuals.Contemporary clinical trials · 2026Article
- The role of the subcortical structures in subthreshold depression: evidence from static and dynamic functional connectivity.Brain structure & function · 2026Article
- Combining neurobiological markers and a sociodemographic risk score to predict adolescent depression - An IDEA RiSCo prospective cohort study.Molecular psychiatry · 2026Article
- Prefrontal Cortex Dysfunction as a Precipitating Factor for Schizophrenia and Depression.Journal of neurochemistry · 2026Review
- Exploring the Impact and Mechanisms of Coffee and Its Active Ingredients on Depression, Anxiety, and Sleep Disorders.Nutrients · 2025Review
- DAMPs cross-talk interpretation of MDD mechanisms.Science advances · 2025Review
- Stress drives myelopoiesis to impair atherosclerosis resolution.Research square · 2025Article
- The immunological perspective of major depressive disorder: unveiling the interactions between central and peripheral immune mechanisms.Journal of neuroinflammation · 2025Review
- Article
- Depicting Coupling Between Cortical Morphology and Functional Networks in Major Depressive Disorder.Depression and anxiety · 2025Article
- Comprehensive Assessment of Physiological and Psychological Responses to Virtual Reality Experiences.Journal of medical extended reality · 2024Article
- A theory of the neural mechanisms underlying negative cognitive bias in major depression.Frontiers in psychiatry · 2024Article
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- Inflammation-Related Functional and Structural Dysconnectivity as a Pathway to Psychopathology.Biological psychiatry · 2023Review
- Towards a multidimensional model of inflamed depression.Brain, behavior, & immunity - health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDepression is characterized by altered neurobiological responses to threat and inflammation may be involved in the development and maintenance of symptoms. However, the mechanistic pathways underlying the relationship between the neural underpinnings of threat, inflammation and depressive symptoms remain unknown.
methodsTwenty participants with major depressive disorder (MDD) and 17 healthy controls (HCs) completed this study. Peripheral blood mononuclear cells (PBMCs) were collected and stimulated ex vivo with lipopolysaccharide (LPS). We then measured a broad array of secreted proteins and performed principal component analysis to compute an aggregated immune reactivity score. Subjects completed a well-validated emotional face processing task during functional magnetic resonance imaging (fMRI). Amygdala activation was measured during perception of threat for the main contrast of interest: fear > happy face. Participants completed the Mood and Anxiety Symptom Questionnaire (MASQ) and the Perceived Stress Scale (PSS). Correlation analyses between amygdala activation, the aggregate immune score, and symptom were computed across groups. A mediation analysis was also performed across groups to further explore the relationship between these three variables.
resultsIn line with our hypotheses and with prior work, the MDD group showed greater amygdala activation in response to threat compared to the HC group [t
conclusionThese data highlight the potential importance of threat circuitry hyperactivation in MDD, consistent with prior reports. We found that higher levels of inflammatory biomarkers were associated with higher amygdala activation, which in turn was associated with anxious arousal. Future research utilizing larger sample sizes are needed to replicate these preliminary results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.